A Drug Interaction Study of SLM0807 and HKB0701 in Healthy Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
An Open-label, Randomized, Crossover Study to Evaluate the Safety and Pharmacokinetics After Multiple Administration of SLM0807 Alone and Multiple Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy volunteers who are in age range of 20-50years and the weight range is not exceed ±20% of ideal weight. Ideal weight = [height -100]*0.9
Subjects with no history of any significant chronic disease
Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data
Available for the entire study period
Willing to adhere to protocol requirements and sign a informed consent form.
Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within 30days prior to drug administration
Subjects who have symptom of an acute illness within 4 weeks prior to drug administration
Subjects with a history of clinically significant allergies including drug allergies
Subjects whose clinical laboratory test values are outside the accepted normal range(Especially,AST or ALT >1.25 times to normal range or total bilirubin > 1.5times to normal range)
Subjects with a history of drug, caffeine or alcohol abuse (caffeine drink >5cups /day, alcohol >30g/day)
Heavy smoker ( >10cigarettes/day)
Subjects who have had a diet known to interfere with the absorption, distribution, metabolism or excretion of drugs (especially, consumption of grapefruit juice)
Subjects who have donated plasma within 60days prior to drug administration
Subjects who have participated in a clinical study within 90days prior to drug administration
Subjects who have received any drugs that might confound the results of the trial in the opinion of principal investigator (cimetidine within 7days prior to drug administration)
Female subjects who are pregnant, breastfeeding or not using medically acceptable birth control